About this trial
In Africa, the mortality from infectious diseases remains high. The investigators have discovered that live vaccines such as the BCG vaccine against tuberculosis and the measles vaccine can strengthen resistance to other infections: they have beneficial "non-specific effects". The investigators have now seen signs that these non-specific effects for children are stronger if their mother has been given the same vaccines.
In Africa, BCG vaccine is recommended at birth and measles vaccine at 9 months of age. They are not used beyond childhood.
The investigators will randomize 2400 women to BCG vaccine, measles vaccine, or placebo. The investigators will further randomize their children to an extra early measles vaccine or placebo. The investigators will assess which of the resulting six vaccination schedules are best for women's and children's protection against measles, for the child's immune system, and for general health.
The project will be the first in the world to investigate the importance of vaccinating women with live vaccines.
Eligibility criteria
Qualifiers
Female women in the fertile age
Non-pregnant
HIV-negative
Living in the BHP HDSS study area
Disqualifiers
Positive pregnancy test
Positive HIV test
Tuberculosis (previous or current)
Immunodeficiency
Trial design
Treatments tested in this trial
- BCG vaccine
- Measles vaccine
- Placebo
Treatment groups
Sponsors and collaborators
Bandim Health Project
Lead sponsor
The University of Western Australia
Collaborator
Université Libre de Bruxelles
Collaborator